West Pharmaceutical Services (NYSE:WST) Announces Quarterly Earnings Results

West Pharmaceutical Services (NYSE:WST) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.46, FiscalAI reports. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. During the same period in the previous year, the company earned $1.96 EPS. The firm’s revenue was up 8.7% on a year-over-year basis.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• Q3 results exceeded expectations: Revenue rose 8.7% reported and 11.9% organically to $874 million, while adjusted EPS increased 36% to $2.66. Management raised full-year 2026 revenue guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48.
• HVP and GLP-1 demand remained strong. HVP Components grew 20% organically, including GLP-1 growth well into the 30% range and high-teens growth outside GLP-1; the company also added more than 200 HVP upgrade projects this year.
• Profitability expanded significantly. Gross margin increased 310 basis points and adjusted operating margin rose 420 basis points year over year, supported by favorable HVP mix, pricing, plant execution and SG&A leverage.
• West is investing to support future growth through HVP finishing-capacity expansions in Europe and the U.S., while targeting CapEx of 6%–8% of revenue. New capacity is expected to come online over roughly 18–24 months, with existing facilities expected to support near-term demand.
• West Vantage remained in transition, with organic revenue down 6.6% as legacy programs, including a CGM program, rolled off faster than new higher-value programs ramped. In addition, the SmartDose 3.5 divestiture is expected to create an approximately 290-basis-point headwind to reported growth in 2027, while free cash flow was down about 5% year to date due mainly to higher receivables and inventory.

West Pharmaceutical Services Stock Up 3.2%

NYSE WST opened at $416.55 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average is $366.60 and its two-hundred day moving average is $312.50. The company has a market capitalization of $29.32 billion, a price-to-earnings ratio of 53.34, a PEG ratio of 2.83 and a beta of 1.13. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $438.27.

West Pharmaceutical Services Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be given a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.2%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette Favorite sold 2,524 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the transaction, the vice president directly owned 21,818 shares of the company’s stock, valued at $7,963,570. This trade represents a 10.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 15,659 shares of company stock valued at $5,443,749. 0.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on WST. Citigroup lifted their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. UBS Group upped their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. KeyCorp increased their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Evercore reissued an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Finally, BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price for the company. Twelve analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $391.17.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Quarterly results exceeded expectations. West reported adjusted EPS of $2.66, ahead of the $2.20 analyst consensus, while revenue rose 8.7% year over year to $874.5 million, topping the $827.1 million estimate. Reported diluted EPS increased 57.3% to $3.02. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 guidance. Full-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion, while adjusted diluted EPS guidance rose to $9.38-$9.48 from $8.85-$9.05. The guidance now slightly exceeds prevailing expectations. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-value products remained the key growth engine. High-Value Product Components sales climbed 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and signaling continued demand for West’s higher-profit pharmaceutical packaging and components. West Pharma Q3 Earnings Rise on HVP Strength

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.